CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Poettler, Marina ^a   Unseld, Matthias ^a   Braemswig, Kira ^a   Haitel, Andrea ^a   Zielinski, Christoph C ^a   Prager, Gerald W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD98; Integrin; Renal cell cancer

Indexed keywords

CD98 ANTIGEN; CD98HC ANTIGEN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CARCINOGENESIS; CD98HC DEFICIENCY; CELL ADHESION; CELL ASSAY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CELL SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY FUNCTION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALIA; MUS;

ANIMALS; ANTIGENS, CD98 HEAVY CHAIN; APOPTOSIS; BINDING SITES; CARCINOMA, RENAL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; HEK293 CELLS; HUMANS; INTEGRINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION;

EID: 84890459561     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-169     Document Type: Article

References (28)

1. Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807):1931-1939. 10.1016/S0140-6736(11)61613-9, 22056247.
2. Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2013, 11:45-50. 10.1016/j.clgc.2012.06.001, 23041453.
3. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012, 107:1665-1671. 10.1038/bjc.2012.385, 3493858, 23132391.
4. Mulders PF. Renal cell carcinoma. World J Urol 2008, 26:113. 10.1007/s00345-008-0248-1, 18389254.
5. Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol 2008, 20:300-306. 10.1097/CCO.0b013e3282f9782b, 18391630.
6. Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, et al. CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest 2009, 39:304-310. 10.1111/j.1365-2362.2009.02096.x, 19292886.
7. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 2005, 102(2):355-360. 10.1073/pnas.0404852102, 544283, 15625115.
8. Tsumura H, Suzuki N, Saito H, Kawano M, Otake S, Kozuka Y, et al. The targeted disruption of the CD98 gene results in embryonic lethality. Biochem Biophys Res Commun 2003, 308:847-851. 10.1016/S0006-291X(03)01473-6, 12927796.
9. Henderson NC, Collis EA, Mackinnon AC, Simpson KJ, Haslett C, Zent R, et al. CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J Biol Chem 2004, 279:54731-54741. 10.1074/jbc.M408700200, 15485886.
10. Rintoul RC, Buttery RC, Mackinnon AC, Wong WS, Mosher D, Haslett C, et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002, 13:2841-2852. 10.1091/mbc.01-11-0530, 117946, 12181350.
11. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997, 390:81-85. 10.1038/36349, 9363894.
12. Zent R, Fenczik CA, Calderwood DA, Liu S, Dellos M, Ginsberg MH. Class- and splice variant-specific association of CD98 with integrin beta cytoplasmic domains. J Biol Chem 2000, 275:5059-5064. 10.1074/jbc.275.7.5059, 10671548.
13. Merlin D, Sitaraman S, Liu X, Eastburn K, Sun J, Kucharzik T, et al. CD98-mediated links between amino acid transport and beta 1 integrin distribution in polarized columnar epithelia. J Biol Chem 2001, 276:39282-39289. 10.1074/jbc.M105077200, 11507094.
14. Miyamoto YJ, Mitchell JS, McIntyre BW. Physical association and functional interaction between beta1 integrin and CD98 on human T lymphocytes. Mol Immunol 2003, 39:739-751. 10.1016/S0161-5890(02)00255-9, 12531285.
15. Stroeken PJ, van Rijthoven EA, Boer E, Geerts D, Roos E. Cytoplasmic domain mutants of beta1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis. Oncogene 2000, 19:1232-1238. 10.1038/sj.onc.1203423, 10713712.
16. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 1995, 130:441-450. 10.1083/jcb.130.2.441, 2199943, 7542248.
17. Parsons M, Keppler MD, Kline A, Messent A, Humphries MJ, Gilchrist R, et al. Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol 2002, 22:5897-5911. 10.1128/MCB.22.16.5897-5911.2002, 133968, 12138200.
18. Prager GW, Feral CC, Kim C, Han J, Ginsberg MH. CD98hc (SLC3A2) Interaction with the Integrin beta Subunit Cytoplasmic Domain Mediates Adhesive Signaling. J Biol Chem 2007, 282:24477-24484. 10.1074/jbc.M702877200, 17597067.
19. Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS, et al. Characterization of a monoclonal antibody (4 F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981, 126:1409-1414.
20. Fenczik CA, Zent R, Dellos M, Calderwood DA, Satriano J, Kelly C, et al. Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem 2001, 276:8746-8752. 10.1074/jbc.M011239200, 11121428.
21. Fogelstrand P, Feral CC, Zargham R, Ginsberg MH. Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2). J Exp Med 2009, 206:2397-2406. 10.1084/jem.20082845, 2768859, 19841087.
22. Boulter E, Estrach S, Errante A, Pons C, Cailleteau L, Tissot F, et al. CD98hc (SLC3A2) regulation of skin homeostasis wanes with age. J Exp Med 2013, 210:173-190. 10.1084/jem.20121651, 3549711, 23296466.
23. Price LS, Leng J, Schwartz MA, Bokoch GM. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell 1998, 9:1863-1871. 10.1091/mbc.9.7.1863, 25428, 9658176.
24. Cai S, Bulus N, Fonseca-Siesser PM, Chen D, Hanks SK, Pozzi A, et al. CD98 modulates integrin beta1 function in polarized epithelial cells. J Cell Sci 2005, 118:889-899. 10.1242/jcs.01674, 15713750.
25. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396. 10.1073/pnas.90.18.8392, 47362, 7690960.
26. Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M, et al. Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature 1999, 402:676-681. 10.1038/45264, 10604475.
27. Sobin LH. International Union Against Cancer TNM Classification of Malignant Tumors 2002, 180-183. New York: Wiley, 6, International Union Against Cancer.
28. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663. 10.1097/00000478-198210000-00007, 7180965.